Fiera Capital Corp Increases Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Posted by Geri Gentry on Jun 9th, 2026

Fiera Capital Corp grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 31.4% during the 4th quarter, HoldingsChannel reports. The fund owned 70,720 shares of the biopharmaceutical company’s stock after purchasing an additional 16,916 shares during the period. Fiera Capital Corp’s holdings in Alnylam Pharmaceuticals were worth $28,122,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. Ameriflex Group Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $32,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $36,000. Newbridge Financial Services Group Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $39,000. Finally, Eastern Bank purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $42,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,740 shares of company stock valued at $2,420,214 in the last ninety days. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $292.16 on Tuesday. The company has a 50 day moving average price of $306.94 and a 200-day moving average price of $347.38. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $283.10 and a fifty-two week high of $495.55. The stock has a market capitalization of $39.01 billion, a PE ratio of 79.83 and a beta of 0.29. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the company earned ($0.44) EPS. The company’s revenue was up 96.4% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Needham & Company LLC reduced their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Finally, Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $463.13.

View Our Latest Stock Analysis on ALNY

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.